Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: A 12-week open-label, multicenter trial

Journal of Sexual Medicine

Volumn 2, Issue 6, 2005, Pages 842-847

  Mirone, Vincenzo ^a   Palmieri, Alessandro ^a   Cucinotta, Domenico ^b   Parazzini, Fabio ^c   Morelli, Patrizia ^d   Bettocchi, Carlo ^e   Fusco, Ferdinando ^a   Montorsi, Francesco ^f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Bayer Medical Department   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Erectile Dysfunction; Global Assessment Question; International Index of Erectile Function; Vardenafil

Indexed keywords

ALANINE AMINOTRANSFERASE; SILDENAFIL; VARDENAFIL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ENZYME DEFECT; ERECTILE DYSFUNCTION; EYE DISEASE; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PRIORITY JOURNAL; PROSTATECTOMY; QUESTIONNAIRE; RHINITIS; SEXUAL INTERCOURSE; SIDE EFFECT; SKIN DISEASE;

EID: 28444499294     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2005.00138.x     Document Type: Article

References (17)

1. Sáenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, Lledo E, Korschen HG, Niewohner U, Haning H, Pages E, Bischoff E. The phosphodyesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001;13:282-90.
2. Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil (Levitra) for erectile dysfunction: A systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004;16:470-8.
3. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new oral selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001;13:192-9.
4. Hellstrom W, Gittelman M, Karlin G, Thibonnier M, Padma-Natan H. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71.
5. Brock G, Nehra A, Lipshultz L, Karlin GS, Cleave M, Seger M, Padma-Nathan H. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003;170:1278-83.
6. Goldstein I, Young JM, Fisher J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
7. Donatucci C, Karlin G, Goldfisher E, Cohen S, Thuibonnier M. Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction. J Am Geriatr Soc 2002;50:S107.
8. Porst H, Young JM, Schmidt AC, Buvat J, International Vardenafil Study Group. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patients subgroups. Urology 2003;62:519-23.
9. Rosen RC, Riley A, Wagner G, Osterloth IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
10. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H, for the European Vardenafil Study Group. The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. Eur Urol 2004;45:634-41.
11. Potempa AJ, Ulbrich E, Bernard I, Beneke M, on behalf of the Vardenafil Study Group. Efficacy of vardenafil in men with erectile dysfunction: A flexible-dose community practice study. Eur Urol 2004;46:73-4.
12. Lewis RW, Sadovsky R, Eardley I, O'Leary M, Seftel A, Wang WC, Shen W, Walker DJ, Wong DG, Ahuja S. The efficacy of tadalafil in clinical populations. J Sex Med 2005;2:517-31.
13. Donatucci C, Eardley I, Buvat J, Gittelman M, Kell P, Segerson T, Homering M, Montorsi F, for the Vardenafil Study Group. Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease. J Sex Med 2004;l:301-9.
14. Mulhall J, Barnas J, Aviv N, Anderson M, Parker M. Sildenafil citrate response correlates with the nature and the severity of penile vascular insufficiency. J Sex Med 2005;2:104-8.
15. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bändel TJ, Porst H for the European Vardenafil Study Group. The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. Eur Urol 2004;45:634-41;
16. editorial comment by Meuleman E: Eur Urol 2004;45:641.
17. Souverein PC, Egberts AC, Meuleman EJ, Urquhart J, Leufkens HG. Incidence and determinants of sildenafil discontinuation: The Dutch cohort of sildenafil users. Int J Impot Res 2002;14:259-65.